Estrella Immunopharma merges wholly-owned sub Estrella Biopharma into parent

Estrella Immunopharma, Inc.

Merger effective June 30, 2024; Estrella Biopharma ceased to exist, Estrella Immunopharma survives.
No changes to management, board, ownership, charter, or bylaws as a result of the merger.
Merger approved by unanimous written consent of board; intended to simplify corporate structure and streamline financial reporting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.